Tonix Q1 net loss $16.8M; cash $131.7M; PDUFA date Aug 15 for TNX-102 SL

Tonix Pharmaceuticals Holding Corp.

2025-Q1 EPS reported -$2.84 revenue$2,429,000

Net loss $16.8M ($2.84/share) vs $14.9M ($535.72/share) in Q1 2024; product revenue $2.4M.
Cash and equivalents $131.7M as of March 31, 2025; cash runway into Q2 2026.
FDA PDUFA goal date Aug 15, 2025 for TNX-102 SL for fibromyalgia; if approved, first new drug in >15 years.
Positive Phase 1 results for TNX-1500 anti-CD40L mAb; plans for Phase 2 in kidney transplant.
Discontinued Phase 2 CATALYST study of TNX-1300 due to slow enrollment; not safety/efficacy.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.